United Kingdom Mounjaro Market Size, Share, Growth, and Industry Analysis, By Indication (Type 2 Diabetes, Obesity/Weight Management, Prediabetes/Metabolic Syndrome, Others), By Route of Administration (Injectable, Oral) and Forecast, 2026-2034

Mounjaro Market Trends

Expansion of Metabolic Therapy Beyond Glycaemic Control

Tirzepatide adoption is moving beyond glucose lowering toward integrated metabolic and weight-management treatment. NICE authorisation covers adults with BMI of at least 30 kg/m², or 27–30 kg/m² with at least 1 weight-related comorbidity, while NHS England introduced a phased primary-care pathway prioritising patients with BMI of 40 kg/m² or more and 4 qualifying comorbidities.

The technology mix is simultaneously shifting toward greater administration convenience. Injectable treatment remains central, but oral incretin innovation is intensifying competitive pressure and could materially expand needle-free adoption. NICE-listed Mounjaro injection prices span £133 for a 4-week 2.5 mg supply to £330 for 12.5 mg and 15 mg doses, demonstrating the substantial pricing differentiation across the 6-dose-strength treatment pathway.

United Kingdom Mounjaro Market Drivers

Rising Diabetes and Obesity Treatment Requirements Accelerate Mounjaro Market Growth

The principal driver is the convergence of diabetes, obesity and cardiometabolic treatment requirements. NHS eligibility expansion creates a sizeable clinical funnel, while NICE recognises tirzepatide alongside diet and exercise for defined type 2 diabetes patients and obesity management. Treatment begins at 2.5 mg and can progress through 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg strengths, creating multiple prescribing stages and sustained medicine volumes. The large overweight and obesity population, combined with 4 major comorbidity criteria in the initial primary-care pathway, supports continuing prescription expansion.

United Kingdom Mounjaro Market Restraints

Eligibility Restrictions, Pricing and Treatment Persistence Limit Wider Uptake

Access remains constrained by clinical eligibility, cost and persistence requirements. NHS England initially restricts primary-care obesity access to patients with BMI ≥40 kg/m² plus 4 qualifying weight-related conditions, while private list pricing ranges from £133 to £330 per 4-week supply depending on strength. NICE diabetes recommendations also apply defined treatment and BMI criteria. These thresholds reduce immediate penetration despite substantial underlying demand, while dose escalation can increase annual acquisition expenditure as patients move from 2.5 mg toward 15 mg.

United Kingdom Mounjaro Market Opportunities

Primary-Care Expansion and Digital Pharmacy Access Create New Commercial Channels

Phased NHS primary-care availability provides a major opportunity alongside specialist services and private digital prescribing. The addressable pathway spans adults with BMI ≥30 kg/m² and overweight adults with BMI ≥27 kg/m² plus at least 1 qualifying comorbidity under the marketing authorisation. Six marketed dose strengths and list prices ranging from £133 to £330 per 4 weeks support differentiated treatment pathways, while online consultation and pharmacy fulfilment can broaden geographic access beyond specialist centres.

Challenges in United Kingdom Mounjaro Market

Supply Scaling, Clinical Governance and Competitive Incretin Innovation Intensify

The key challenge is balancing rapid patient uptake with prescribing governance, supply availability and long-term treatment monitoring. NICE's 2026 diabetes guidance recommends stepwise medicine introduction and checking tolerability and effectiveness, while GLP-1 therapies and tirzepatide should not be combined with DPP-4 inhibitors. Competition is also expanding as oral GLP-1 technologies develop, increasing pressure across injectable products, 6 Mounjaro dose strengths and private versus NHS channels.

Mounjaro Market Segmentation

The market is segmented by indication, route of administration, dosage strength and distribution channel. Type 2 diabetes holds 40.82% of indication revenue in 2026, while injectable delivery captures 62.17% of route-based revenue. Obesity/weight management and oral administration are the fastest-growing categories at 20.53% and 21.09% CAGR, respectively.

By Indication

Type 2 diabetes is the largest indication, increasing from USD 426.02 million in 2025 to USD 508.28 million in 2026 and USD 2,087.00 million by 2034, representing a 19.31% CAGR. Its 2026 contribution is 40.82%, compared with 34.14% for obesity/weight management, 15.04% for prediabetes/metabolic syndrome and 10.00% for other indications.

Obesity/weight management is the fastest-growing indication at 20.53% CAGR, ahead of prediabetes/metabolic syndrome at 20.11%, type 2 diabetes at 19.31% and others at 18.55%. Obesity revenue advances from USD 425.01 million in 2026 to USD 1,893.06 million by 2034.

By Route of Administration

Injectable administration is the largest route, valued at USD 770.73 million in 2026 compared with USD 652.33 million in 2025 and USD 2,926.65 million in 2034, reflecting an 18.15% CAGR. Injectables represent 62.17% of the supplied route-based 2026 total.

Oral administration is the fastest-growing route at 21.09% CAGR, rising from USD 468.91 million in 2026 to USD 2,167.48 million by 2034. Its contribution consequently increases from 37.83% in 2026 to approximately 42.55% by 2034.

By Dosage Strength

The dosage-strength structure comprises 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg presentations. Treatment titration supports recurring demand across 6 strengths, while current NICE-listed 4-week prices range from £133 at 2.5 mg and £180 at 5 mg to £255 at 7.5–10 mg and £330 at 12.5–15 mg.

No dosage-strength revenue or CAGR values were supplied; therefore, numerical market leadership or fastest-growing strength is not assigned. Clinical titration nevertheless creates sequential utilization across the 2.5–15 mg range.

By Distribution Channel

Distribution spans retail pharmacies, hospital pharmacies, online pharmacies and specialty pharmacies. NHS specialist weight-management services have supplied eligible obesity patients since March 23, 2025, with primary-care availability being phased toward eligible high-need patients.

No channel-specific revenue or CAGR dataset was supplied, so market leadership is not numerically assigned. Retail and online channels remain important for private prescriptions, while hospital, specialist and primary-care pathways support NHS-treated populations.

United Kingdom Mounjaro Market Outlook

England represents the principal geographic contributor because it contains roughly 84% of the UK population and operates the largest NHS treatment infrastructure. Its initial primary-care pathway targets BMI ≥40 kg/m² patients with 4 qualifying comorbidities, complementing specialist services and substantial private prescribing activity.

Scotland, Wales and Northern Ireland collectively account for roughly 16% of the UK population and provide additional expansion potential through devolved healthcare systems, retail pharmacies and private digital channels. Exact county or nation revenue shares and production volumes were not supplied; consequently, geographic market values are not extrapolated from the mandatory national dataset.

Top players in United Kingdom Mounjaro Market

• Eli Lilly and Company
• Novo Nordisk A/S
• AstraZeneca PLC
• Pfizer Inc.
• Roche Holding AG
• Boehringer Ingelheim
• Sanofi S.A.
• Amgen Inc.
• Zealand Pharma A/S
• Structure Therapeutics Inc.
• Viking Therapeutics Inc.
• Regeneron Pharmaceuticals Inc.

Top Two Companies

• Eli Lilly and Company

Mounjaro's manufacturer holds the defining position in the UK tirzepatide category, with the product authorised for type 2 diabetes and weight management. Its commercial advantage includes 6 dose strengths from 2.5 mg to 15 mg and NHS/private-channel availability. Because company-level UK revenue shares were not supplied or publicly verified, an exact percentage share is not assigned.

• Novo Nordisk A/S

Novo Nordisk is the principal branded incretin competitor through its semaglutide portfolio. Competition spans diabetes, obesity, injectable and increasingly oral treatment formats. Its position places sustained pressure on pricing, patient acquisition and administration convenience; however, no verified UK Mounjaro-category company-share percentage was supplied, so an unsupported percentage is not presented.

Recent Developments in United Kingdom Mounjaro Market

• 2026:NICE updated type 2 diabetes guidance, including recommendations concerning tirzepatide use, sequencing and treatment review.
• 2026:NICE guidance states tirzepatide can be considered for certain early-onset type 2 diabetes patients alongside established therapies.
• 2025:NHS England implemented phased Mounjaro access for weight management, with specialist-service access from March 23, 2025 and primary-care rollout focused initially on highest clinical need.
• 2025:NICE's tirzepatide diabetes appraisal was updated on September 1, retaining recommendations for specified adult populations and a commercial access arrangement.
• 2024:NICE published TA1026 for tirzepatide in overweight and obesity management on December 23, establishing defined BMI and comorbidity criteria.

Research Methodology

The analysis uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast period, with 2022–2024 treated as historical years. Mandatory supplied tables are the primary source for revenue, contribution and CAGR calculations. The indication dataset establishes USD 1,245.07 million for 2026 and USD 5,276.97 million for 2034 at 19.62% CAGR. The separately supplied route dataset totals USD 1,239.64 million in 2026 and USD 5,094.13 million in 2034; this discrepancy is retained rather than artificially reconciled. Secondary validation uses NICE and NHS England sources for regulatory status, eligibility, pricing and clinical pathways. No unsupported segment, regional or company revenue figures were manufactured where source data were unavailable.